Brought to you by 
Forest boosts depression portfolio in $1.1bn acquisition of Clinical Data
27 Oct 2020
Executive Summary
Forest Laboratories Inc. is acquiring publicly traded Clinical Data Inc. for $30 per share in cash (a 3% discount), valuing the agreement at $928.6mm up front based on 31mm in outstanding Clinical Data stock. Clinical Data’s shareholders are also entitled to as much as $185.7mm in cash earn-outs tied to the revenues of the company’s Viibryd (vilazodone), which was approved last month by the FDA for major depressive disorder in adults.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Forest boosts depression portfolio in $1.1bn acquisition of Clinical Data
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice